Zurcher Kantonalbank Zurich Cantonalbank Purchases 3,983 Shares of Glaukos Co. (NYSE:GKOS)

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 36.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,939 shares of the medical instruments supplier's stock after purchasing an additional 3,983 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Glaukos were worth $2,240,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its holdings in Glaukos by 186.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,726 shares of the medical instruments supplier's stock worth $1,788,000 after purchasing an additional 8,942 shares in the last quarter. First Turn Management LLC acquired a new position in shares of Glaukos during the 3rd quarter worth about $12,520,000. Harbor Capital Advisors Inc. acquired a new position in shares of Glaukos during the 4th quarter worth about $3,679,000. Victory Capital Management Inc. boosted its stake in shares of Glaukos by 421.8% during the 3rd quarter. Victory Capital Management Inc. now owns 79,211 shares of the medical instruments supplier's stock worth $10,320,000 after buying an additional 64,031 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Glaukos by 5.3% during the 3rd quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier's stock worth $254,626,000 after buying an additional 98,109 shares during the last quarter. Institutional investors own 99.04% of the company's stock.

Remove Ads

Insider Transactions at Glaukos

In other news, insider Tomas Navratil sold 3,416 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Joseph E. Gilliam sold 3,328 shares of the firm's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $149.85, for a total transaction of $498,700.80. Following the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at $15,310,024.65. This represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,744 shares of company stock valued at $2,504,131. 6.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on GKOS shares. Wells Fargo & Company increased their price objective on shares of Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Piper Sandler restated an "overweight" rating and set a $180.00 price objective (up from $140.00) on shares of Glaukos in a research note on Monday, January 27th. Mizuho upgraded shares of Glaukos from a "neutral" rating to an "outperform" rating and increased their price objective for the stock from $140.00 to $200.00 in a research note on Wednesday, February 19th. Citigroup upgraded shares of Glaukos from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $132.00 to $162.00 in a research note on Wednesday, December 11th. Finally, Stephens upgraded shares of Glaukos to a "strong-buy" rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Glaukos has an average rating of "Moderate Buy" and an average target price of $163.25.

Glaukos Stock Performance

GKOS stock traded down $0.38 during mid-day trading on Thursday, hitting $100.86. 772,764 shares of the company were exchanged, compared to its average volume of 583,468. The business has a 50 day simple moving average of $137.56 and a 200-day simple moving average of $137.00. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $5.71 billion, a PE ratio of -35.14 and a beta of 0.99. Glaukos Co. has a 1-year low of $85.31 and a 1-year high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The company had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. On average, equities analysts forecast that Glaukos Co. will post -1.08 earnings per share for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.